Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study
- PMID: 26770906
- PMCID: PMC4706125
- DOI: 10.2147/RRU.S97194
Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study
Abstract
Peyronie's disease (PD) is a chronic disorder involving the tunica albuginea surrounding the corpora cavernosa of the penis. A conservative treatment is indicated in the first stage of disease. The aim of this study was to assess the therapeutic impact and possible side effects of treatment with pentoxifylline (PTX) in combination with other antioxidants in 307 patients with early-stage PD. Patients were subdivided into three groups: A, B, and C. Both groups, A and B, comprising of 206 patients, underwent treatment, whereas Group C was the control group (n=101). Treatment lasted 6 months and included the following: Group A: PTX 400 mg twice a day + propolis 600 mg/d + blueberry 160 mg/d + vitamin E 600 mg/d + diclofenac 4% gel twice/a day + PTX 100 mg via perilesional penile injection/every other week (12 injections in all); Group B: the same treatment as Group A except for the penile PTX injections. After the 6-month treatment course, we obtained the following results: actual mean decrease in plaque volume -46.9% and -24.8% in Group A and B, respectively (P<0.0001); mean curvature reduction -10.1° and -4.8°, respectively (P,0.0001); resolution of pain in 67.6% and 67.2% of cases, respectively (P=0.961); recovery of normal penile rigidity in 56.09% and 23.5% of cases, respectively (P=0.005). After 6 months, progression of disease was observed in all patients belonging to Group C: plaque volume +123.3%; curvature +15.7°; no recovery of penile rigidity. The statistically significant results of our study show that multimodal treatment with PTX in association with other antioxidants and topical diclofenac is efficacious in treating early-stage PD. Furthermore, treatment proved to be more effective when PTX was administered both orally and by penile injection. No serious adverse effects occurred.
Keywords: antioxidant supplementation; multimodal treatment; penile curvature; penile injections.
Similar articles
-
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.Res Rep Urol. 2017 Jul 20;9:129-139. doi: 10.2147/RRU.S141748. eCollection 2017. Res Rep Urol. 2017. PMID: 28791261 Free PMC article.
-
Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.J Med Case Rep. 2022 Oct 8;16(1):359. doi: 10.1186/s13256-022-03614-1. J Med Case Rep. 2022. PMID: 36207748 Free PMC article.
-
Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases.Am J Case Rep. 2022 Apr 17;23:e936146. doi: 10.12659/AJCR.936146. Am J Case Rep. 2022. PMID: 35430575 Free PMC article.
-
Review of Management Options for Patients With Atypical Peyronie's Disease.Sex Med Rev. 2017 Apr;5(2):211-221. doi: 10.1016/j.sxmr.2016.07.004. Epub 2016 Aug 17. Sex Med Rev. 2017. PMID: 27544298 Review.
-
Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.Inflamm Allergy Drug Targets. 2012 Feb;11(1):48-57. doi: 10.2174/187152812798889321. Inflamm Allergy Drug Targets. 2012. PMID: 22309083 Review.
Cited by
-
Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.Int J Impot Res. 2022 Apr;34(3):280-288. doi: 10.1038/s41443-021-00430-x. Epub 2021 Apr 7. Int J Impot Res. 2022. PMID: 33828265 Free PMC article.
-
Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants.Int J Mol Sci. 2022 Dec 15;23(24):15969. doi: 10.3390/ijms232415969. Int J Mol Sci. 2022. PMID: 36555611 Free PMC article. Review.
-
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.Res Rep Urol. 2017 Jul 20;9:129-139. doi: 10.2147/RRU.S141748. eCollection 2017. Res Rep Urol. 2017. PMID: 28791261 Free PMC article.
-
Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Curr Urol Rep. 2021 Jan 8;22(2):6. doi: 10.1007/s11934-020-01024-8. Curr Urol Rep. 2021. PMID: 33420664 Review.
-
Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.J Med Case Rep. 2022 Oct 8;16(1):359. doi: 10.1186/s13256-022-03614-1. J Med Case Rep. 2022. PMID: 36207748 Free PMC article.
References
-
- Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88:727–730. - PubMed
-
- Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–2353. - PubMed
-
- Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou XA. Population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. [Accessed November 18, 2015];Adv Urol. 2011 2011:282503. doi: 10.1155/2011/282503. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202120/pdf/AU2011-282503.pdf. - DOI - PMC - PubMed
-
- Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJ. Therapeutic advances in the treatment of Peyronie’s disease. Andrology. 2015;3(4):650–660. - PubMed
-
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources